Clinical trial NCT02479087 - References

Hemophilia A — Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

Citation(s)

•   Aznar JA, Lorenzo JI, Molina R, Haya S, Querol F, Dasí MA
  Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Haemophilia. 1998 Jan;4(1):21-4.
•   Bentorp E, Ekman M, Gunnarson M
  Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations Haemophilia 1996; 2: 95-99
•   Colowick AB, Bohn RL, Avorn J, Ewenstein BM
  Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 2000 Sep 1;96(5):1698-702.
•   Coppola A, Di Minno MN, Santagostino E
  Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010 Sep;150(5):515-28. doi: 10.1111/j.1365-2141.2010.08263.x. Epub 2010 Jun 22. Review.
•   Gensana M, Altisent C, Aznar JA, Casaña P, Hernández F, Jorquera JI, Magallón M, Massot M, Puig L
  Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001 Jul;7(4):369-74.
•   Gensana M, Altisent C
  Aznar JA, Casana P, Hernandez F, Jorquera JI, Magallon M, Massot M, Puig L. Factor VIII inhibitors directed to the A2 domain and the light chain may also show less reactivity to FVIII complexed with VWF. World Federation of Haemophilia, The Hague, May 1998, (Abstract book).
•   Gilles JG, Saint-Remy JMR
  Recombinant and plasma-derived factor VIII are immunologically distinct in in vitro assays. Thromb Haemost 1995; 73:1213.
•   Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group
  Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007 Jul;13(4):373-9.
•   Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, et al
  Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost. 1995 Feb;73(2):215-8.
•   Hay CR, DiMichele DM; International Immune Tolerance Study
  The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18.
•   Haya S, Casaña P, Moret A, Cid RA, Cabrera N, Abad L, Aznar AJ
  Immunotolerance Induction Treatments in Hemophilia. J.of Coagulation Disorders 2009; 1(1): 37-42.
•   Kreutz W: Immune tolerance induction (ITI) in Haemophilia A-patients with inhibitors - the choice of concentrate affecting success
  Haematologica 2001; 86 (S4):16-20
•   Kreuz W, Steiner J, Auerswald G, Beeg T, Becker S
  Successful immunetolerance therapy of FVIII-inhibitor in chldren after changing from high to intermediate purity FVIII concentrate. Ann Hematol 1996; 72 (suppl 1).
•   Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM
  Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995 Aug 1;86(3):983-8.
•   Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B
  Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005 Sep;90(9):1288-90.
•   Rokicka-Milewska R, Klukowska A, Dreger B, Beer H-J
  Incidence of factor VIII inhibitor development in previously untreated Haemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Ann Hematol 1999; 78 (suppl 1)
•   Smith MP, Rice KM, Savidge GF
  Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment. Thromb Haemost. 1997 Feb;77(2):406-7.
•   Sukhu K, Keeling DM, Giangrande PL
  Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clin Lab Haematol. 2000 Oct;22(5):287-90.
•   Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K
  Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost. 1996 Nov;76(5):749-54.
•   Teitel JM
  Safety of coagulation factor concentrates. Haemophilia. 1998 Jul;4(4):393-401. Review.
•   Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ
  Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost. 1997 Sep;78(3):1027-9.

IMMUNE TOLERANCE INDUCTION, BY FACTOR VIII CONCENTRATE CONTAINING VON WILLEBRAND FACTOR, IN SEVERE OR MODERATE HAEMOPHILIA A PATIENTS WITH INHIBITORS

Details for clinical trial NCT02479087